AstraZeneca has admitted that its COVID-19 vaccine could cause a rare but deadly blood-clotting condition, potentially exposing the UK pharmaceutical giant to tens of millions in lawsuits brought by loved ones of those injured or killed as a result of the jab, according to court documents.
Lawyers representing “dozens” of class-action claimants say some of their clients’ cases could be worth as much as $25 million, calling the Cambridge-headquartered pharma firm’s vaccine “a defective product,” according to the Daily Mail.
AstraZeneca, which is contesting the claims, acknowledged in a February legal document that its vaccine can “in very rare cases” cause a condition called thrombosis with thrombocytopenia syndrome, or TTS.
TTS can cause patients to suffer blood clots as well as a low blood platelet count, which in some cases have seriously harmed or even killed recipients of the company’s vaccine.
The potential complication was listed as a possible side effect from the time of the vaccine’s release, but AstraZeneca’s acknowledgment in February marks the first time the pharmaceutical titan has admitted it in court, according to the Telegraph.
So far, 51 cases have been filed in London’s High Court, estimated to be worth around $125 million total, the outlet writes.
Due to a bargain AstraZeneca struck with the UK government at the height of the pandemic to indemnify the drugmaker against potential lawsuits, taxpayers will be on the hook for any payouts resulting from the claims.
One of the claimants who filed suit is Jamie Scott, an IT engineer and father of two left with a permanent brain injury resulting from a blood clot after he received the vaccine in April 2021. --->READ MORE HERE
 |
| Dake Kang/AP |
The first scientist to publish a sequence of the COVID-19 virus in China staged a sit-in protest outside his lab after authorities locked him out of the facility — a sign of the Beijing's continuing pressure on scientists conducting research on the coronavirus.
Zhang Yongzhen wrote in an online post Monday that he and his team had been suddenly notified they were being evicted from their lab, the latest in a series of setbacks, demotions and ousters since the virologist published the sequence in January 2020 without state approval.
When Zhang tried to go to the lab over the weekend, guards barred him from entering. In protest, he sat outside on flattened cardboard in drizzling rain, pictures from the scene posted online show. News of the protest spread widely on Chinese social media and Zhang told a colleague he slept outside the lab — but it was not clear Tuesday if he remained there.
“I won’t leave, I won’t quit, I am pursuing science and the truth!” he wrote in a post on Chinese social media platform Weibo that was later deleted.
In an online statement, the Shanghai Public Health Clinical Center said that Zhang’s lab was being renovated and was closed for “safety reasons.” It added that it had provided Zhang’s team an alternative laboratory space.
But Zhang wrote online that his team wasn’t offered an alternative until after they were notified of their eviction, and that the lab offered didn’t meet safety standards for conducting their research, leaving his team in limbo.
Zhang’s latest difficulty reflects how China has sought to control information related to the virus: An Associated Press investigation found that the government froze meaningful domestic and international efforts to trace it from the first weeks of the outbreak. That pattern continues to this day, with labs closed, collaborations shattered, foreign scientists forced out and Chinese researchers barred from leaving the country. --->READ MORE HEREFollow links below to relevant/related stories and resources:
COVID-19 hospitalizations hit record low, the CDC says
COVID-19-induced financial hardships reveal mental health struggles
USA TODAY: Coronavirus Updates
WSJ: Coronavirus Live Updates
YAHOO NEWS: Coronavirus Live Updates
NEW YORK POST: Coronavirus The Latest
If you like what you see, please "Like" and/or Follow us on FACEBOOK here, GETTR here, and TWITTER here.
No comments:
Post a Comment